RS61668B1 - Lečenje multiplog mijeloma (mm) - Google Patents

Lečenje multiplog mijeloma (mm)

Info

Publication number
RS61668B1
RS61668B1 RS20210419A RSP20210419A RS61668B1 RS 61668 B1 RS61668 B1 RS 61668B1 RS 20210419 A RS20210419 A RS 20210419A RS P20210419 A RSP20210419 A RS P20210419A RS 61668 B1 RS61668 B1 RS 61668B1
Authority
RS
Serbia
Prior art keywords
antibody
patients
multiple myeloma
mor202
seq
Prior art date
Application number
RS20210419A
Other languages
English (en)
Serbian (sr)
Inventor
Stéphane Leclair
Jan Endell
Stefan Härtle
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of RS61668B1 publication Critical patent/RS61668B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
RS20210419A 2015-05-13 2016-05-13 Lečenje multiplog mijeloma (mm) RS61668B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167597 2015-05-13
EP16723349.3A EP3294769B1 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (mm)
PCT/EP2016/060810 WO2016180958A1 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (mm)

Publications (1)

Publication Number Publication Date
RS61668B1 true RS61668B1 (sr) 2021-04-29

Family

ID=53174925

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210419A RS61668B1 (sr) 2015-05-13 2016-05-13 Lečenje multiplog mijeloma (mm)

Country Status (24)

Country Link
US (2) US10533057B2 (enExample)
EP (1) EP3294769B1 (enExample)
JP (2) JP7160533B2 (enExample)
KR (1) KR20180008571A (enExample)
CN (1) CN107614530A (enExample)
AU (1) AU2016260895B2 (enExample)
CA (1) CA2984464C (enExample)
CY (1) CY1123982T1 (enExample)
DK (1) DK3294769T3 (enExample)
ES (1) ES2862708T3 (enExample)
HR (1) HRP20210552T1 (enExample)
HU (1) HUE054271T2 (enExample)
IL (1) IL255552B (enExample)
LT (1) LT3294769T (enExample)
MX (1) MX380557B (enExample)
PL (1) PL3294769T3 (enExample)
PT (1) PT3294769T (enExample)
RS (1) RS61668B1 (enExample)
RU (1) RU2723047C2 (enExample)
SG (1) SG11201708691VA (enExample)
SI (1) SI3294769T1 (enExample)
SM (1) SMT202100202T1 (enExample)
WO (1) WO2016180958A1 (enExample)
ZA (1) ZA201708386B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2016180958A1 (en) * 2015-05-13 2016-11-17 Morphosys Ag Treatment for multiple myeloma (mm)
BR112019000544A2 (pt) 2016-07-15 2019-04-24 Takeda Pharmaceutical Company Limited métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática
EP3737702A1 (en) 2018-01-12 2020-11-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
KR20250117714A (ko) * 2018-03-28 2025-08-05 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투약
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
EP3893841A1 (en) * 2018-12-14 2021-10-20 MorphoSys AG Antibody formulations
US11939390B2 (en) * 2019-01-28 2024-03-26 Sanofi-Aventis U.S. Llc Methods of treating multiple myeloma
WO2020194242A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with pomalidomide and dexamethasone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
JP2003524587A (ja) 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
EP2799451A1 (en) 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
RU2425841C2 (ru) 2005-10-12 2011-08-10 МорфоСис АГ Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
SI2068874T1 (sl) * 2006-08-07 2015-06-30 Abbvie Biotherapeutics Inc. Postopki zdravljenja multiplega mieloma z uporabo kombinacijske terapije utemeljene na anti-csi protitelesih
HRP20191115T1 (hr) * 2006-09-26 2019-09-20 Genmab A/S Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DK2580243T3 (da) * 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
WO2014089279A1 (en) * 2012-12-05 2014-06-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds
CN103421115B (zh) * 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
BR112016009403A2 (pt) * 2013-10-31 2017-09-19 Sanofi Sa Anticorpos anti-cd38 específicos para tratamento de cânceres humanos
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
WO2016180958A1 (en) * 2015-05-13 2016-11-17 Morphosys Ag Treatment for multiple myeloma (mm)

Also Published As

Publication number Publication date
CY1123982T1 (el) 2022-05-27
MX2017014396A (es) 2018-03-23
ZA201708386B (en) 2019-06-26
WO2016180958A1 (en) 2016-11-17
LT3294769T (lt) 2021-04-26
US11591406B2 (en) 2023-02-28
JP2018515513A (ja) 2018-06-14
KR20180008571A (ko) 2018-01-24
RU2723047C2 (ru) 2020-06-08
US10533057B2 (en) 2020-01-14
ES2862708T3 (es) 2021-10-07
HRP20210552T1 (hr) 2021-05-14
CA2984464C (en) 2023-10-10
DK3294769T3 (da) 2021-03-08
HUE054271T2 (hu) 2021-08-30
PT3294769T (pt) 2021-04-13
SMT202100202T1 (it) 2021-05-07
JP2021130668A (ja) 2021-09-09
MX380557B (es) 2025-03-12
CN107614530A (zh) 2018-01-19
SG11201708691VA (en) 2017-11-29
CA2984464A1 (en) 2016-11-17
AU2016260895A1 (en) 2017-11-09
IL255552B (en) 2022-01-01
US20190048091A1 (en) 2019-02-14
RU2017137496A3 (enExample) 2019-06-13
JP7160533B2 (ja) 2022-10-25
PL3294769T3 (pl) 2021-07-05
EP3294769A1 (en) 2018-03-21
RU2017137496A (ru) 2019-06-13
AU2016260895B2 (en) 2021-08-05
EP3294769B1 (en) 2021-01-13
SI3294769T1 (sl) 2021-07-30
US20200079871A1 (en) 2020-03-12
IL255552A (en) 2018-01-31

Similar Documents

Publication Publication Date Title
US11591406B2 (en) Treatment for multiple myeloma (MM)
CN104684552B (zh) 组合及其用途
RU2723937C2 (ru) Композиции, включающие антитела к cd38 и карфилзомиб
JP2016506388A (ja) 抗ｃｄ３８抗体及びレナリドマイドを含む組成物
KR20240117655A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
CN113993543B (zh) 使用抗cd38抗体的组合疗法
KR20240035816A (ko) 항-pla2r 자가항체-매개성 막성 신장병증의 치료
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
HK1247939A1 (en) Treatment for multiple myeloma (mm)
TW202547859A (zh) 抗人類pd-l1抗體及其用途
HK1210949B (zh) 组合及其用途